Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 153

Results For "ABI"

3664 News Found

Ami Organics accredited Gold Medal by EcoVadis
Sustainability | April 16, 2024

Ami Organics accredited Gold Medal by EcoVadis

The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally


Moderna pauses plan to build mRNA manufacturing facility in Kenya
News | April 16, 2024

Moderna pauses plan to build mRNA manufacturing facility in Kenya

The demand in Africa for COVID-19 vaccines has declined


Generics gain ground, yet HCPs still favor branded drugs, finds GlobalData
News | April 12, 2024

Generics gain ground, yet HCPs still favor branded drugs, finds GlobalData

A significant proportion of healthcare professionals still tend to favor branded drugs


Evonik launches Botanicals & Natural Actives business segment
News | April 11, 2024

Evonik launches Botanicals & Natural Actives business segment

Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market


Pluss unveils Celsure XL VIP pallets
News | April 07, 2024

Pluss unveils Celsure XL VIP pallets

A game changing solution for the pharmaceutical industry


Wacker and Pantherna intensify collaboration in the development and production of mRNA biopharmaceuticals
Biotech | April 07, 2024

Wacker and Pantherna intensify collaboration in the development and production of mRNA biopharmaceuticals

Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry


Dabur India expects mid-single digit revenue growth in Q4
News | April 05, 2024

Dabur India expects mid-single digit revenue growth in Q4

International Business is expected to register double-digit growth in constant currency terms


Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
Clinical Trials | April 05, 2024

Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084

For the first-line treatment of certain patients with metastatic non-small cell lung cancer